Efficacy of antidepressants in animal models of ischemic stroke: A systematic review and meta-analysis

Stroke

Volumn 45, Issue 10, 2014, Pages 3055-3063

  McCann, Sarah K ^a   Irvine, Cadi ^b   Mead, Gillian E ^b   Sena, Emily S ^a,b   Currie, Gillian L ^b   Egan, Kieren E ^b   Macleod, Malcolm R ^b   Howells, David W ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

animal; antidepressive agents; meta analysis; models; review; stroke; systematic

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL WELFARE; ARTICLE; BODY TEMPERATURE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CLINICAL TRIAL (TOPIC); COGNITION; DRUG EFFICACY; LEARNING; MEMORY; META ANALYSIS; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW; ANIMAL; CEREBROVASCULAR ACCIDENT; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; HUMAN; PATHOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; DISEASE MODELS, ANIMAL; HUMANS; RECOVERY OF FUNCTION; STROKE;

EID: 84930160708     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006304     Document Type: Article

References (29)

1. Hackett ML, Anderson CS, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane Database Syst Rev. 2008:CD003689.
2. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008:CD003437.
3. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. Lancet Neurol. 2011;10:123-130.
4. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009;87:1037-1045.
5. Shin TK, Kang MS, Lee HY, Seo MS, Kim SG, Kim CD, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean J Physiol Pharmacol. 2009;13:257-263.
6. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007;18:391-418.
7. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008;28:1374-1384.
8. Coppell AL, Pei Q, Zetterström TS. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology. 2003;44:903-910.
9. Russo-Neustadt AA, Beard RC, Huang YM, Cotman CW. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience. 2000;101:305-312.
10. Mikami K, Jorge RE, Adams HP Jr, Davis PH, Leira EC, Jang M, et al. Effect of antidepressants on the course of disability following stroke. Am J Geriatr Psychiatry. 2011;19:1007-1015.
11. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365-2372.
12. Nikisch G, Mathé AA, Czernik A, Thiele J, Bohner J, Eap CB, et al. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology (Berl). 2005;181:751-760.
13. Barugh AJ, Gray P, Shenkin SD, MacLullich AM, Mead GE. Cortisol levels and the severity and outcomes of acute stroke: A systematic review. J Neurol. 2014;261:533-545.
14. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
15. Howells DW, Sena ES, O'Collins V, Macleod MR. Improving the efficiency of the development of drugs for stroke. Int J Stroke. 2012;7:371-377.
16. van der Worp HB, Macleod MR, Bath PM, Demotes J, Durand-Zaleski I, Gebhardt B, et al; EuroHYP-1 investigators. EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke. Int J Stroke. 2014;9:642-645.
17. Sena ES, Currie GL, McCann SK, Macleod MR, Howells DW. Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically. J Cereb Blood Flow Metab. 2014;34:737-742.
18. Macleod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004;35:1203-1208.
19. Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, et al. Meta-analysis of data from animal studies: A practical guide. J Neurosci Methods. 2014;221:92-102.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
21. Light RJ, Pillemer DB. Summing Up: The Science of Reviewing Research. Cambridge, MA: Harvard University Press; 1984.
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
23. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463.
24. Pedder H, Vesterinen HM, Macleod MR, Wardlaw JM. Systematic review and meta-analysis of interventions tested in animal models of lacunar stroke. Stroke. 2014;45:563-570.
25. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab. 2005;25:713-721.
26. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. J Neurol. 2009;256:1152-1158.
27. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001;50:718-729.
28. Vesterinen HM, Currie GL, Carter S, Mee S, Watzlawick R, Egan KJ, et al. Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke. Syst Rev. 2013;2:33.
29. Rooke ED, Vesterinen HM, Sena ES, Egan KJ, Macleod MR. Dopamine agonists in animal models of Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17:313-320.